[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Sabo D, Bernd L, Buchner M, Treiber M, Wannenmacher M, Ewerbeck V, Parsch D: [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors]. Orthopade; 2003 Nov;32(11):1003-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors].
  • In 13 patients with primary malignant bone tumors (10 Ewing's sarcoma, 1 parosteal osteosarcoma, 1 adamantinoma recurrence, and 1 MFH) local therapy was performed as intraoperative extracorporeal irradiation and replantation (IEIR) of the involved bone segment (5 tibia, 2 femur, and 6 pelvis).
  • Of the 13 patients (69%), 9 are alive at the time of the follow-up (5 CDF, 4 AWM(treated)) and 4 patients died of disease (DOD).
  • IEIR must be seen as an extraordinary reconstruction procedure in cases where established procedures such as endoprosthesis, biological reconstructions, or rotationplasties cannot be used or are refused by the patient.
  • [MeSH-minor] Adolescent. Adult. Aged. Ameloblastoma / drug therapy. Ameloblastoma / pathology. Ameloblastoma / radiotherapy. Ameloblastoma / surgery. Child, Preschool. Combined Modality Therapy. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Follow-Up Studies. Histiocytic Sarcoma / drug therapy. Histiocytic Sarcoma / pathology. Histiocytic Sarcoma / radiotherapy. Histiocytic Sarcoma / surgery. Humans. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / surgery. Radiotherapy Dosage. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / surgery. Tibia / pathology. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1988 May-Jun;200(3):243-52 [3145357.001]
  • [Cites] J Bone Joint Surg Am. 1987 Apr;69(4):583-95 [2952660.001]
  • [Cites] Orthop Clin North Am. 1987 Apr;18(2):275-89 [3550576.001]
  • [Cites] Langenbecks Arch Surg. 2003 Jan;387(9-10):355-65 [12536331.001]
  • [Cites] Acta Orthop Scand. 1996 Dec;67(6):583-8 [9065072.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):613-30 [7046906.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3685-90 [12552977.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):54-64 [7822356.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1992 Jul-Aug;130(4):285-9 [1413973.001]
  • [Cites] J Bone Joint Surg Br. 1988 May;70(3):348-53 [3163694.001]
  • [Cites] J Orthop Res. 1985;3(4):389-404 [3906062.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1017-21 [6883269.001]
  • [Cites] Unfallchirurg. 1999 Jul;102(7):580-8 [10459306.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):223-30 [1884544.001]
  • [Cites] Int Orthop. 1998;22(1):32-6 [9580457.001]
  • [Cites] Int Orthop. 1997;21(5):283-90 [9476156.001]
  • [Cites] Acta Orthop Scand. 1988 Feb;59(1):34-8 [3128053.001]
  • [Cites] J Bone Joint Surg Br. 2000 Mar;82(2):276-82 [10755441.001]
  • [Cites] J Bone Joint Surg Am. 1986 Mar;68(3):362-9 [3456348.001]
  • [Cites] J Bone Joint Surg Am. 1991 Sep;73(8):1123-42 [1890115.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):196-206 [10613169.001]
  • [Cites] Clin Orthop Relat Res. 1993 Oct;(295):226-38 [8403653.001]
  • [Cites] Clin Orthop Relat Res. 1990 Feb;(251):249-53 [2295182.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1991;77(1):6-13 [1829244.001]
  • (PMID = 14615850.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Kumamoto H, Ohki K: Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors. J Oral Pathol Med; 2010 Jan;39(1):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue specimens of 12 tooth germs, 47 ameloblastomas, and six malignant ameloblastic tumors were examined using reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry to determine the expression of CD133, Bmi-1, and ABCG2.
  • Immunohistochemical reactivity for CD133 and Bmi-1 was evident in odontogenic epithelial cells neighboring the basement membrane in tooth germs, ameloblastomas, and metastasizing ameloblastomas, and ameloblastic carcinomas and clear cell odontogenic carcinomas showed reactivity for CD133 and Bmi-1 in most neoplastic cells.
  • The level of CD133 immunoreactivity in malignant ameloblastic tumors was significantly higher than the levels in tooth germs and ameloblastomas.
  • Some granular neoplastic cells in granular cell ameloblastomas showed ABCG2 expression.
  • The level of ABCG2 immunoreactivity in malignant ameloblastic tumors was significantly higher than that in tooth germs.
  • Expression of these molecules is possibly involved in oncogenesis, cell differentiation, and malignant potential of odontogenic epithelium.
  • [MeSH-major] ATP-Binding Cassette Transporters / analysis. Ameloblastoma / pathology. Antigens, CD / analysis. Glycoproteins / analysis. Neoplasm Proteins / analysis. Nuclear Proteins / analysis. Peptides / analysis. Proto-Oncogene Proteins / analysis. Repressor Proteins / analysis. Zinc Fingers
  • [MeSH-minor] AC133 Antigen. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Basement Membrane / pathology. Cell Differentiation. Cell Nucleus / ultrastructure. Drug Resistance, Multiple. Enamel Organ / pathology. Endothelial Cells / pathology. Epithelial Cells / pathology. Fibroblasts / pathology. Humans. Immunohistochemistry. Odontogenic Tumors / pathology. Polycomb Repressive Complex 1. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / pathology. Tooth Germ / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19659474.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 Antigen; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, CD; 0 / BMI1 protein, human; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / PROM1 protein, human; 0 / Peptides; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 2.3.2.27 / Polycomb Repressive Complex 1
  •  go-up   go-down


Advertisement
3. Kumamoto H, Yoshida M, Ooya K: Immunohistochemical detection of hepatocyte growth factor, transforming growth factor-beta and their receptors in epithelial odontogenic tumors. J Oral Pathol Med; 2002 Oct;31(9):539-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumors derived from odontogenic epithelium exhibit considerable variation and are classified into several benign and malignant entities.
  • METHODS: Specimens of five tooth germs, 34 ameloblastomas, three calcifying epithelial odontogenic tumors (CEOTs), two clear cell odontogenic tumors (CCOTs), five adenomatoid odontogenic tumors (AOTs), six calcifying odontogenic cysts (COCs) and six malignant ameloblastomas were examined immunohistochemically with the use of antibodies against HGF, TGF-beta and their receptors.
  • In tooth germs and main types of ameloblastomas, HGF and TGF-beta reactivity was marked in epithelial cells near the basement membrane, and their receptors were diffusely positive in most epithelial cells.
  • In subtypes of ameloblastomas, reduced expression of HGF, c-Met and TGF-beta and increased reactivity for TGF-beta receptors were detected in keratinizing cells in acanthomatous ameloblastomas, and granular cells in granular cell ameloblastomas demonstrated little or no expression of HGF, TGF-beta or their receptors.
  • As compared with main types of ameloblastomas, basal cell ameloblastomas showed high HGF reactivity, and desmoplastic ameloblastomas exhibited elevated reactivity for TGF-beta and its receptors.
  • Metastasizing ameloblastomas showed similar expression patterns of HGF, TGF-beta and their receptors to those of benign ameloblastomas, while CCOTs and ameloblastic carcinomas had increased HGF expression and low reactivity for TGF-beta and its receptors as compared with benign ameloblastomas.
  • Altered expression of the agents in these epithelial odontogenic tumors, especially subtypes of ameloblastomas, AOTs and COCs, suggests that HGF and TGF-beta signaling might affect differentiation of neoplastic odontogenic epithelial cells.
  • Activated HGF/c-Met pathway and reduced TGF-beta signaling in CCOTs and ameloblastic carcinomas may be associated with the malignant potential of these epithelial odontogenic tumors.
  • [MeSH-minor] Cell Transformation, Neoplastic. Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-met / analysis. Proto-Oncogene Proteins c-met / biosynthesis. Receptors, Transforming Growth Factor beta / analysis. Receptors, Transforming Growth Factor beta / biosynthesis. Tooth Germ / chemistry. Tooth Germ / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269993.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down






Advertisement